Moderna announced on Tuesday that their coronavirus vaccine is 90 percent effective six months after someone gets their second dose.
Vaccine efficacy from two weeks after the second dose and based on the updated reviewed cases remains consistent with previous updates, including over 90% against all cases of COVID-19 and over 95% against severe cases of COVID-19 , ” the company announced
Moderna is working to have its vaccine fully approved by the US, as it is only under emergency Food and Drug Administration permits.
“The Moderna team continues to make significant progress with our COVID-19 vaccine,” said Stéphane Bancel, CEO of Moderna. “The new preclinical data on our variant-specific vaccine candidates gives us confidence that we can proactively address emerging variants.”
The study includes data from 900 coronavirus cases, of which more than 100 are serious cases.
Along with the updated vaccine efficacy, Moderna is currently working on the second phase for testing in adolescents.
There are approximately 3,000 minors between the ages of 12 and 17 who are fully enrolled in Moderna’s process, and the company is working to enroll children from 6 months to 11 years of age.
The company aims to fully enroll 6,750 healthy pediatric participants in the US and Canada.
News of Moderna’s success comes when the FDA recommended interrupting the Johnson & Johnson vaccine due to concerns about blood clots.